Drug intelligence / Profile preview

AXN-001

Development stage: Unknown
Lead developer: Axonova Pharma
Modality: Peptides
Administration: Subcutaneous, Intravenous

Overview

AXN-001 is a peptide CGRP-R antagonist under development by Axon Therapeutics for the acute treatment of migraine. This investigational drug is designed to block the calcitonin gene-related peptide receptor (CGRP-R), a key target in migraine pathophysiology. It is being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics, with a subcutaneous formulation intended for self-administration.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on AXN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXN-001.

Explore the full profile